Selected article for: "final concentration and mm final concentration"

Author: Stuart Weston; Rob Haupt; James Logue; Krystal Matthews; Matthew B. Frieman
Title: FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro
  • Document date: 2020_3_27
  • ID: jbc74lcu_5
    Snippet: Vero E6 cells (ATCC# CRL 1586) were cultured in DMEM (Quality Biological), supplemented with 10% (v/v) fetal bovine serum (Sigma), 1% (v/v) penicillin/streptomycin (Gemini Bioproducts) and 1% (v/v) L-glutamine (2 mM final concentration, Gibco). Cells were maintained at 37°C and 5% CO2. Samples of SARS-CoV-2 were obtained from the CDC following isolation from a patient in Washington State (WA-1 strain -BEI #NR-52281). Stocks were prepared by infe.....
    Document: Vero E6 cells (ATCC# CRL 1586) were cultured in DMEM (Quality Biological), supplemented with 10% (v/v) fetal bovine serum (Sigma), 1% (v/v) penicillin/streptomycin (Gemini Bioproducts) and 1% (v/v) L-glutamine (2 mM final concentration, Gibco). Cells were maintained at 37°C and 5% CO2. Samples of SARS-CoV-2 were obtained from the CDC following isolation from a patient in Washington State (WA-1 strain -BEI #NR-52281). Stocks were prepared by infection of Vero E6 cells for two days when CPE was starting to be visible. Media were collected and clarified by centrifugation prior to being aliquoted for storage at -80°C. Titer of stock was determined by plaque assay using Vero E6 cells as described previously (6) . All work with infectious virus was performed in a Biosafety Level 3 laboratory and approved by our Institutional Biosafety Committee.

    Search related documents:
    Co phrase search for related documents